Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy

BACKGROUND: Recently, anti-CD38 monoclonal antibody (Mab) therapy has become a focus of attention as an additional/alternative option for many hematological neoplasms including T-cell acute lymphoblastic leukemia (T-ALL). It has been shown that antitumor efficacy of anti-CD38-Mab depends on the leve...

Descripción completa

Detalles Bibliográficos
Autores principales: Tembhare, Prashant Ramesh, Sriram, Harshini, Khanka, Twinkle, Chatterjee, Gaurav, Panda, Devasis, Ghogale, Sitaram, Badrinath, Yajamanam, Deshpande, Nilesh, Patkar, Nikhil V, Narula, Gaurav, Bagal, Bhausaheb, Jain, Hasmukh, Sengar, Manju, Khattry, Navin, Banavali, Shripad, Gujral, Sumeet, Subramanian, Papagudi G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247386/
https://www.ncbi.nlm.nih.gov/pubmed/32439800
http://dx.doi.org/10.1136/jitc-2020-000630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247386/
https://www.ncbi.nlm.nih.gov/pubmed/32439800
http://dx.doi.org/10.1136/jitc-2020-000630

Ejemplares similares